Impact of corona virus (COVID-19) on Targovax’s operations
Oslo, Norway, 20 March 2020 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, issues an update to its investors and analysts. Targovax is running clinical trials at several hospitals both in Europe and the US. Targovax management is following the COVID-19 outbreak situation closely and is continuously working to find mitigating solutions as the situation continues. In the short term there are no significant implications to our core operations. Following the outbreak of COVID-19, authorities on both